Clinical Research on Recombinant Ⅶa Factor for the Treatment of Hypertensive Cerebral Hem-orrhage with Coagulation Disorder

王建清,盖延廷,徐福林,胡锦,孙一睿
DOI: https://doi.org/10.3969/j.issn.1671-7171.2013.09.020
2013-01-01
Abstract:[Objective]To explore the safety and value of middle and low dose of recombinant Ⅶa factor (rFⅦa)for the treatment of patients with hypertensive cerebral hemorrhage.[Methods]A prospective single-centre case control study was conducted.A total of 168 patients with hypertensive cerebral hemorrhage from Aug 2011 to Jan 2013 were admitted in our hospital.According to the recruitment criteria,86 patients were enrolled in this study including 27 patients in experiment group and 59 patients in control group.In the experi-ment group,patients were injected with rFⅦa 20 μg/kg within 2 hours after admission.Glasgow coma scale (GCS)and coagulation parameters of two groups at admission were recorded and compared.The amount of blood transfusion,length of stay in ICU,medical expense,mortality on day 30,and GOS on day 90 were fol-lowed up.[Results]Compared with before treatment,coagulation parameters in two groups after treatment were improved.Compared with control group,international normalized ratio(INR)was decreased(0.29±0.23 v.s 0.11 ± 0.39)and prothrombin time(PT)was shortened in the experiment group(3.26±2.53 v.s 1.85± 4.5)which were better than the control group,and there were significant differences(P <0.05).GOS score of patients was evaluated during 3 months of follow up.The prognosis of patients in the experiment group showed slight better,but there was no significant difference.[Conclusion]rFⅦa for the treatment of cerebral hemorrhage can improve the coagulation of patients,but its correlation with the prognosis needs further inves-tigation by large-sample clinical data.
What problem does this paper attempt to address?